GHRS

Conviction 58HealthcareScan · Thu, Sep 24, 2026

GH Research PLC (GHRS) closed at $24.42 (-5.93%) on Sep 24, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 30, RS Rating 92, -20.3% from its 52-week high, +84.4% year to date. Sector: Healthcare · Biotechnology.

GHRS$24.42-5.93%

ResistanceSupportVol 14

Vol MA14 217.55K

Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24

GH Research PLCBiotechnologywww.ghres.com ↗

Price24.42

Change-5.93%

Gap+1.14%

Rel volume3.47×

Avg volume203.99K

Avg $ vol5.55M

SMA 2027.57

SMA 5028.30

SMA 20020.67

Price vs 50-13.72%

Price vs 200+18.14%

MA stackmixed

50/200 cross—

Supertrenddown · 29.08

RSI (14)30

MACD hist-0.28

MACD crossbear · 1d

Stoch %K / %D17 / 26

ADX (14)19

+DI / −DI12 / 33

RSI divergence—

MACD divergence—

ATR %5.62%

ADR %4.56%

52w high30.64

52w low12.49

From 52w high-20.30%

Above 52w low+95.59%

New 52w highNo

SqueezeOn · 9d

Bollinger width13.55%

%B-0.34

Donchian pos17.12%

Donchian high29.17

Donchian low23.44

AVWAP (52w high)28.48

vs AVWAP high-14.27%

AVWAP (52w low)20.78

vs AVWAP low+17.53%

OBV trendDown

Chaikin MF (20)-0.03

Today vs 20d3.47×

Avg vol (14d)217.55K

Avg vol (20d)203.99K

Avg $ vol (20d)5.55M

Market cap1.51B

RS Rating92 / 99

RS 3m (vs SPY)-8.12%

RS 6m (vs SPY)+62.08%

RS line new highNo

Trend template6/8

Technical rank60.7

1 week-14.97%

1 month-15.56%

3 months-3.63%

6 months+78.90%

1 year+78.90%

YTD+84.44%

P/E—

P/B—

P/S—

P/FCF—

EPS—

Div yield—

ROE—

ROA—

Debt/Eq—

Current—

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth—

Price target43.38

Target upside77.64%

Analyst ratingBuy

Institutional75.06%

Ent. value1.51B

Revenue—

Net income—

Gross profit—

Free cash flow—

IndustryBiotechnology

ExchangeNasdaq

Shares out68.61M

Employees73

ListedFri, Jun 25, 2021

Free float45.24M

Float %72.9%

Short interest3.08M

Days to cover18.5d

Short volume28.8%

Squeeze score54 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.23 vs −$0.31

Last surprise+25.8% beat

Setup gradeC

Conviction58 / 100

Pattern quality—

Tech rank60.7 / 100

Group rank59 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance31.00

Support26.53

Days since event—

Candle confirm—

Congress activity

Disclosed STOCK Act trades in GHRS

All disclosures →

No recent disclosed trades by Congress in GHRS. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in GHRS

Insider	Side	Shares	Value	Traded	Filed
Schonharting Florian Director · Share Options (Right to Buy) · 2026-09-08	Grant	2.3K	—	2026-09-08	2026-09-09
Moore Duncan Director · Share Options (Right to Buy) · 2026-08-11	Grant	2.2K	—	2026-08-11	2026-08-13
Forer Michael Director · Share Options (Right to Buy) · 2026-08-11	Grant	2.2K	—	2026-08-11	2026-08-13
Forer Michael Director · Share Options (Right to Buy) · 2026-08-11	Grant	100K	—	2026-08-11	2026-08-13
Hanley Dermot John Director · Share Options (Right to Buy) · 2026-08-11	Grant	2.2K	—	2026-08-11	2026-08-13

SEC filings

EDGAR filings in GHRS · 6 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.